Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Additional Prognostic Impact of the Percentage of Erythroid Cells in the Bone Marrow of MDS Patients

Judith Neukirchen, MD, Heinz Tuechler, Matteo Giovanni Della Porta, MD, Pierre Fenaux, MD PhD, Ulrich Germing, MD, Agnès Guerci, Kathrin Nachtkamp, MD, Marianna Rossi, MD, Rosa Sapena, Wolfgang R. Sperr, MD, Corinna Strupp, MD, Aspasia Stamatoullas, MD, Peter Valent, MD, John M. Bennett, MD

Blood (2017) 130 (Supplement 1): 4259.

https://doi.org/10.1182/blood.V130.Suppl_1.4259.4259

Published: 2017

Journal Articles

Survey of Treatment of 1021 Patients with Myelodysplastic Syndromes in a Tertiary Referal Center 2007-2013

Jennifer Schemenau, Kathrin Nachtkamp, MD, Blanca Xicoy, MD PhD, Andrea Kuendgen, MD, Corinna Strupp, MD, Thomas Schroeder, MD, Esther Schuler, Guido Kobbe, MD, Norbert Gattermann, MD, Rainer Haas, MD, Ulrich Germing

Blood (2014) 124 (21): 4647.

https://doi.org/10.1182/blood.V124.21.4647.4647

Published: 2014

Journal Articles

In MDS Del(5q), Factors Other Than Age and Sex Distribution Contribute to the Prognostic Advantage, Which Diminishes over Time

Michael Lauseker, PhD, Jennifer Schemenau, Corinna Strupp, MD, Andrea Kuendgen, MD, Norbert Gattermann, MD, Joerg Hasford, MD, Ulrich Germing, MD

Blood (2014) 124 (21): 3271.

https://doi.org/10.1182/blood.V124.21.3271.3271

Published: 2014

Journal Articles

A WHO Classification-Based Prognostic Scoring System (WPSS) for Predicting Survival in Myelodysplastic Syndromes.

Luca Malcovati, MD, Ulrich Germing, MD, Andrea Kuendgen, MD, Matteo G. Della Porta, MD, Rosangela Invernizzi, MD, Aristoteles Giagounidis, MD, Barbara Hildebrandt, PhD, Paolo Bernasconi, MD, Sabine Knipp, MD, Mario Lazzarino, MD, Corinna Strupp, MD, Mario Cazzola, MD

Blood (2005) 106 (11): 788.

https://doi.org/10.1182/blood.V106.11.788.788

Published: 2005

Journal Articles

Phase 2 Trial of the Histone Deacetylase Inhibitor Valproic Acid as a Monotherapy or in Combination with All-Trans Retinoic Acid in 24 Patients with Acute Myeloid Leukemia.

Andrea Kuendgen, MD, Corinna Strupp, MD, Barbara Hildebrandt, PhD, Sabine Knipp, MD, Baerbel Junge, Rainer Haas, MD, Ulrich Germing, MD, Norbert Gattermann, MD

Blood (2004) 104 (11): 1808.

https://doi.org/10.1182/blood.V104.11.1808.1808

Published: 2004

NARROW

Additional Prognostic Impact of the Percentage of Erythroid Cells in the Bone Marrow of MDS Patients

Survey of Treatment of 1021 Patients with Myelodysplastic Syndromes in a Tertiary Referal Center 2007-2013

In MDS Del(5q), Factors Other Than Age and Sex Distribution Contribute to the Prognostic Advantage, Which Diminishes over Time

A WHO Classification-Based Prognostic Scoring System (WPSS) for Predicting Survival in Myelodysplastic Syndromes.

Phase 2 Trial of the Histone Deacetylase Inhibitor Valproic Acid as a Monotherapy or in Combination with All-Trans Retinoic Acid in 24 Patients with Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Additional Prognostic Impact of the Percentage of Erythroid Cells in the Bone Marrow of MDS Patients

Survey of Treatment of 1021 Patients with Myelodysplastic Syndromes in a Tertiary Referal Center 2007-2013

In MDS Del(5q), Factors Other Than Age and Sex Distribution Contribute to the Prognostic Advantage, Which Diminishes over Time

A WHO Classification-Based Prognostic Scoring System (WPSS) for Predicting Survival in Myelodysplastic Syndromes.

Phase 2 Trial of the Histone Deacetylase Inhibitor Valproic Acid as a Monotherapy or in Combination with All-Trans Retinoic Acid in 24 Patients with Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only